

Efficient asymmetric synthesis of lamivudine *via* enzymatic dynamic kinetic resolution†

Lei Hu, Fredrik Schaufelberger, Yan Zhang and Olof Ramström\*

Cite this: *Chem. Commun.*, 2013, **49**, 10376Received 22nd July 2013,  
Accepted 9th September 2013

DOI: 10.1039/c3cc45551c

www.rsc.org/chemcomm

The anti-HIV nucleoside lamivudine was asymmetrically synthesized in only three steps *via* a novel surfactant-treated subtilisin Carlsberg-catalyzed dynamic kinetic resolution protocol. The enantiomer of lamivudine could also be accessed using the same protocol catalyzed by *Candida antarctica* lipase B.

In the last decade, lamivudine (3TC, **1a**) (Fig. 1) has proven to be one of the most successful agents for the treatment of HIV as well as chronic Hepatitis B.<sup>1</sup> The compound inhibits both type 1 and type 2 of the human HIV reverse transcriptase and also the reverse transcriptase of hepatitis B *in vitro*.<sup>2–6</sup> As a permanent cure for HIV has remained elusive to date, efficient access to bulk quantities of lamivudine is synthetically very valuable as continuous demand is expected. There are several reported methods to synthesize isomerically pure lamivudine. Most of the previous reports introduced the chiral 1,3-oxathiolane motif by either crystallizing the correct isomer from a racemic mixture,<sup>7,8</sup> or by enzymatic hydrolysis/acetylation of the other stereoisomers.<sup>9–11</sup> For example, Liotta and Koszalka developed an efficient six-step pathway to racemic nucleosides and utilized a late-stage enzymatic kinetic resolution with a series of lipases to esterify the undesired enantiomer. Lamivudine was then obtained in good enantiomeric excess but moderate yield.<sup>10</sup> The major disadvantage of these methods is the great loss of yield due to the nature of the kinetic resolution process, as no more than 50% yield could be theoretically achieved while maintaining high enantiomeric purity. In 2005, Goodyear *et al.* employed a crystallization-induced dynamic kinetic

resolution (DKR) method for the lamivudine synthesis,<sup>12</sup> however requiring not only seven steps of synthesis, and undesirable reagents such as SOCl<sub>2</sub>, but also the use of chiral auxiliary-derived starting materials.

Compared with other commonly used catalysts for asymmetric synthesis, such as chiral transition-metal complexes and organo-catalysts, biocatalysis is now becoming a highly potent alternative in both academia and the pharmaceutical industry.<sup>13–16</sup> This is in part due to the high stereoselectivities that can be obtained, the potential to modify/optimize the performances through directed evolution protocols, the inherent environmentally benign (green) nature of the catalysts, and the ease of recycling processes.<sup>17–25</sup> In this study, we report a highly efficient three-step asymmetric synthesis of lamivudine and its enantiomer through a novel enzyme-catalyzed DKR protocol based on reversible formation of the intermediate stereoisomers. The key enantioenriched 1,3-oxathiolane structure was obtained in good yield and enantiopurity from two achiral starting materials through an enzyme-catalyzed cascade addition–cyclization–acetylation reaction, leading directly to a suitable substrate for the subsequent Vorbrüggen coupling reaction that is most frequently used for nucleoside synthesis. The advantage of this strategy is obvious, as the formation of the hemiacetal and its transformation into a better leaving group for the subsequent coupling are performed in one pot. In addition, by using different types of enzymes, the stereochemical configuration of the oxathiolane intermediate could be easily controlled, dynamically yielding the precursor of lamivudine or its enantiomer (Fig. 1), respectively. This sets up a useful example for the construction of highly enantioenriched oxathiolane-based nucleosides with access to both enantiomers in a short synthetic route. The method represents an improvement to the previous lamivudine syntheses with respect to both efficiency and environmental friendliness.

Taking advantage of the dynamic formation of hemithioacetals,<sup>26,27</sup> we recently reported that *Candida antarctica* lipase B (CAL B) catalyzes the cyclization of the intermediate generated from the reversible nucleophilic addition of sulfanylacetal **2** to aldehyde **3**, asymmetrically forming 1,3-oxathiolan-5-one derivative **4** (Scheme 1).<sup>19</sup> Since the core structures of compounds **1** and **4** are





Fig. 1 Lamivudine (**1a**) and its enantiomer (**1b**).

Royal Institute of Technology, Department of Chemistry, Teknikringen 30, Stockholm, Sweden. E-mail: ramstrom@kth.se; Fax: +46 8 7912333

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3cc45551c




**Scheme 1** CAL B-catalyzed synthesis of 1,3-oxathiolan-5-ones.


very similar, the possibility of applying the same strategy to the enzyme-catalyzed asymmetric synthesis of lamivudine appeared to be natural.

Initially, compounds **5** and **6** were mixed with triethylamine (TEA) as the base and phenyl acetate as the acyl donor in the presence of CAL B in toluene (Scheme 2). The intention was that compounds **5** and **6** would react to form compound **7b** (2*R*) (Scheme 3) in a one-pot cyclization–diol acetylation reaction. According to the  $^1\text{H}$  NMR and chiral HPLC analyses, an enantioenriched intermediate was obtained in 88% yield, with 6.8:1 dr, and 83% ee after two days. To elucidate the absolute configuration of precursor **7**, the asymmetric nucleoside was synthesized through a modified Vorbrüggen coupling and deacylation procedure.<sup>28–30</sup> The overall yield for this three-step asymmetric synthesis was 37%. Chiral HPLC was then used to identify the selectivity of CAL B by analyzing samples from both the CAL B-catalyzed nucleoside synthesis and commercial lamivudine. The result showed that the amplified isomer was compound **1b**; therefore it could be deduced that CAL B selectively enriched the undesired intermediate stereoisomer **7a** (2*S*). Nine different lipases were subsequently screened: the lipases from *Candida rugosa*, *Rhizopus niveus*, *Rhizopus arrhizus*, porcine pancreas, *Penicillium camemberti*, *Aspergillus niger*, *Pseudomonas fluorescens*, *Burkholderia (Pseudomonas) cepacia*, and *Candida antarctica* lipase A. Of these, the lipases from *Burkholderia cepacia* and *Pseudomonas fluorescens* were also able to catalyze the formation of the cyclized intermediate, showing similar stereochemical preferences to CAL B.

In order to obtain the correct stereoisomer, an enzyme with different stereoselectivity was required. The protease subtilisin



**Scheme 2** Synthesis of *ent*-lamivudine (**1b**) using CAL B; (i) phenyl acetate, CAL B, TEA, toluene, rt, 92%; (ii) silylated *N*<sup>4</sup>-acetylcytosine, TMSI, MeCN, 0 °C; (iii)  $\text{K}_2\text{CO}_3$ , MeOH, rt, 40% for two steps.




**Scheme 3** Synthesis of intermediate **7b** with STS; rt, 87%.

Carlsberg is known to have the opposite selectivity for acyclic secondary alcohols compared to the selectivities of many lipases.<sup>31–34</sup> The commercially available subtilisin Carlsberg was thus treated with octyl  $\beta$ -D-glucopyranoside and Brij 56 to enhance its activity and stability in organic solvents.<sup>35</sup> The surfactant-treated subtilisin Carlsberg (STS) was applied to the same reaction conditions as in Scheme 2. Upon comparing the intermediate with compound **7a**, it is clear that STS selected enantiomer **7b** (Scheme 3), which would lead to the asymmetric synthesis of lamivudine. However, unsatisfactory enantiomeric purities (up to 64% ee) were obtained, despite extensive screening of the reaction conditions.

In order to obtain higher ees from the enzymatic DKR reaction, benzoyl protected aldehyde **8** was chosen instead of glycolaldehyde dimer **5** to react with 1,4-dithiane-2,5-diol **6** in the presence of STS (Scheme 4), assuming that the larger structure would fit the enzyme active site more rigidly. This substrate was subjected to similar reaction conditions as depicted in Scheme 2 for two days. The isolated intermediate **9a** was obtained with an enantiomeric purity of 45% ee, which was promising for the further optimization. After Vorbrüggen coupling and deprotection, the final product (40% overall yield for three steps) was again compared with the standard sample using chiral HPLC, and the result showed that lamivudine (**1a**) was still amplified over its enantiomer under these conditions.

With the correct isomer in hand, several parameters were screened to improve the STS-mediated DKR protocol (Table 1). TBME and THF were tested as enzyme-tolerable solvents besides toluene according to the previous studies.<sup>17,19–21,23,27</sup> The results in TBME were very similar to those obtained in toluene, whereas increased dr and ee from 2:1 and 45% to 4.3:1 and 65%, respectively, were obtained in THF, indicating that STS favors more polar solvents. Varying the amount of base and enzyme loading did not significantly affect the yield and selectivity. The performances of STS at different temperatures were also addressed. The highest yield was obtained at 40 °C but with very low stereoselectivity. Both the dr and ee could however be well improved by lowering the temperature from 25 °C to 4 °C without significant loss of efficiency. Lowering the temperature further gave even higher selectivities, although resulting in lower STS activity, where the highest enantiomeric purity (85% ee) could be recorded at –18 °C.




**Scheme 4** Synthesis of lamivudine (**1a**) using STS: (i) phenyl acetate, STS, TEA, THF, 4 °C, 89%; (ii) silylated *N*<sup>4</sup>-acetylcytosine, TMSI, MeCN, 0 °C, 51%; (iii)  $\text{K}_2\text{CO}_3$ , MeOH, rt, 89%.



**Table 1** Optimization of the DKR conditions<sup>a</sup>

Entry	Solvent	T [°C]	STS [mg]	dr <sup>b</sup>	ee <sup>c</sup> [%]	Yield <sup>d</sup> [%]
1	Toluene	25	20	2.0 : 1	45	74
2	TBME	25	20	2.5 : 1	47	69
3	THF	25	20	4.3 : 1	67	92
4	THF	25	10	4.9 : 1	67	81
5	THF	25	30	4.5 : 1	68	92
6	THF	4	20	4.3 : 1	82	89
7	THF	-18	20	4.3 : 1	85	23

<sup>a</sup> Reaction conditions: 0.1 mmol **8**, 0.06 mmol **6**, 0.1 mmol TEA, 0.3 mmol phenyl acetate; 2 d. <sup>b</sup> Estimated by <sup>1</sup>H NMR spectroscopy from the isolated racemic mixture. <sup>c</sup> Analyzed by chiral HPLC (Chiralpak OJ column, λ = 254 nm) using 10% of 2-propanol in hexane. <sup>d</sup> Isolated yield.

**Scheme 5** Synthesis of intermediate **9b** with CAL B; rt, 83%.

To verify the selectivity pattern of CAL B for the same substrates, the reaction was carried out under the optimized conditions for two days. Chiral HPLC analysis revealed that CAL B selectively formed isomer **9b** (84% ee) (Scheme 5), the enantiomer of the STS-catalyzed intermediate **9a**, indicating the retained selectivity of CAL B in spite of different starting materials.

In summary, we have developed a three-step asymmetric synthesis of lamivudine using surfactant-treated subtilisin Carlsberg as a green catalyst. This strategy represents a first entry to efficient high-enantiopurity nucleoside analog synthesis, whereby application of enzyme optimization techniques, such as rational redesign or directed evolution protocols, could lead to enhanced selectivities. We have also described that the stereochemistry of the target molecules could be well controlled, as different isomers of the nucleoside intermediates were selectively obtained using different enzymes. This study thus offers a valuable methodology for the asymmetric synthesis of lamivudine as well as other nucleosides such as emtricitabine and apricitabine, where specific stereoisomers are desired.

This work was in part supported by the Swedish Research Council and the Royal Institute of Technology. LH and YZ thank the China Scholarship Council for special scholarship awards.

## Notes and references

- G. Romeo, U. Chiacchio, A. Corsaro and P. Merino, *Chem. Rev.*, 2010, **110**, 3337.
- J. W. Beach, L. S. Jeong, A. J. Alves, D. Pohl, H. O. Kim, C. N. Chang, S. L. Doong, R. F. Schinazi, Y. C. Cheng and C. K. Chu, *J. Org. Chem.*, 1992, **57**, 2217.
- C. N. Chang, S. L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C. H. Tsai, Y. C. Cheng, D. Liotta and R. Schinazi, *J. Biol. Chem.*, 1992, **267**, 13938.
- J. A. Coates, N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner and J. M. Cameron, *Antimicrob. Agents Chemother.*, 1992, **36**, 733.
- L. S. Jeong, R. F. Schinazi, J. W. Beach, H. O. Kim, S. Nampalli, K. Shanmuganathan, A. J. Alves, A. McMillan, C. K. Chu and R. Mathis, *J. Med. Chem.*, 1993, **36**, 181.
- S. L. Doong, C. H. Tsai, R. F. Schinazi, D. C. Liotta and Y. C. Cheng, *Proc. Natl. Acad. Sci. U. S. A.*, 1991, **88**, 8495.
- J.-Z. Li, L.-X. Gao and M.-X. Ding, *Synth. Commun.*, 2002, **32**, 2355.
- B. N. Roy, G. P. Singh, D. Srivastava, H. S. Jadhav, M. B. Saini and U. P. Aher, *Org. Process Res. Dev.*, 2009, **13**, 450.
- J. Milton, S. Brand, M. F. Jones and C. M. Rayner, *Tetrahedron Lett.*, 1995, **36**, 6961.
- L. K. Hoong, L. E. Strange, D. C. Liotta, G. W. Koszalka, C. L. Burns and R. F. Schinazi, *J. Org. Chem.*, 1992, **57**, 5563.
- R. P. C. Cousins, M. Mahmoudian and P. M. Youds, *Tetrahedron: Asymmetry*, 1995, **6**, 393.
- M. D. Goodyear, M. L. Hill, J. P. West and A. J. Whitehead, *Tetrahedron Lett.*, 2005, **46**, 8535.
- M. T. Reetz, in *Adv. Catal.*, ed. C. G. Bruce and K. z. Helmut, Academic Press, 2006, vol. 49, p. 1.
- M. Ikunaka, *Chem.-Eur. J.*, 2003, **9**, 378.
- M. T. Reetz, *Angew. Chem., Int. Ed.*, 2002, **41**, 1335.
- E. M. Anderson, K. M. Larsson and O. Kirk, *Biocatal. Biotransform.*, 1998, **16**, 181.
- P. Vongvilai, R. Larsson and O. Ramström, *Adv. Synth. Catal.*, 2008, **350**, 448.
- H. E. Schoemaker, D. Mink and M. G. Wubboldts, *Science*, 2003, **299**, 1694.
- M. Sakulsombat, Y. Zhang and O. Ramström, *Chem.-Eur. J.*, 2012, **18**, 6129.
- P. Vongvilai and O. Ramström, *J. Am. Chem. Soc.*, 2009, **131**, 14419.
- P. Vongvilai, M. Angelin, R. Larsson and O. Ramström, *Angew. Chem., Int. Ed.*, 2007, **46**, 948.
- R. Larsson and O. Ramström, *Eur. J. Org. Chem.*, 2006, 285.
- M. Sakulsombat, P. Vongvilai and O. Ramström, *Org. Biomol. Chem.*, 2011, **9**, 1112.
- M. Breuer, K. Ditrach, T. Habicher, B. Hauer, M. Keßler, R. Stürmer and T. Zelinski, *Angew. Chem., Int. Ed.*, 2004, **43**, 788.
- A. Houde, A. Kademi and D. Leblanc, *Appl. Biochem. Biotechnol.*, 2004, **118**, 155.
- R. Caraballo, H. Dong, J. P. Ribeiro, J. Jiménez-Barbero and O. Ramström, *Angew. Chem., Int. Ed.*, 2010, **49**, 589.
- M. Sakulsombat, M. Angelin and O. Ramström, *Tetrahedron Lett.*, 2010, **51**, 75.
- H. Jin, M. A. Siddiqui, C. A. Evans, H. L. A. Tse, T. S. Mansour, M. D. Goodyear, P. Ravenscroft and C. D. Beels, *J. Org. Chem.*, 1995, **60**, 2621.
- W. B. Choi, L. J. Wilson, S. Yeola, D. C. Liotta and R. F. Schinazi, *J. Am. Chem. Soc.*, 1991, **113**, 9377.
- H. Vorbrüggen and C. Ruh-Pohlentz, *Organic Reactions*, John Wiley & Sons, Inc., 2004.
- R. J. Kazlauskas, A. N. E. Weissfloch, A. T. Rappaport and L. A. Cuccia, *J. Org. Chem.*, 1991, **56**, 2656.
- M.-J. Kim, Y. I. Chung, Y. K. Choi, H. K. Lee, D. Kim and J. Park, *J. Am. Chem. Soc.*, 2003, **125**, 11494.
- L. Borén, B. Martín-Matute, Y. Xu, A. Córdova and J.-E. Bäckvall, *Chem.-Eur. J.*, 2006, **12**, 225.
- R. J. Kazlauskas and A. N. E. Weissfloch, *J. Mol. Catal. B: Enzym.*, 1997, **3**, 65.
- L. K. Thälén, A. Sumic, K. Bogár, J. Norinder, A. K. Ö. Persson and J.-E. Bäckvall, *J. Org. Chem.*, 2010, **75**, 6842.

